Gene · 5890
Papers1,861
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 1,861
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. | JCO Precis Oncol | 2023 | 36623239 | PubTator, text mining | PubMed |
| Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers. | Nat Commun | 2023 | 36611031 | PubTator, text mining | PubMed |
| Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis. | Nat Commun | 2023 | 36604421 | PubTator, text mining | PubMed |
| Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma. | JAMA Netw Open | 2023 | 36602798 | PubTator, text mining | PubMed |
| Lipoblastoma in one adult and 35 pediatric patients: Retrospective analysis of 36 cases. | Exp Ther Med | 2023 | 36561624 | PubTator, text mining | PubMed |
| The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma. | Cancer Sci | 2023 | 36541483 | PubTator, text mining | PubMed |
| Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer. | Breast Cancer Res Treat | 2023 | 36494460 | PubTator, text mining | PubMed |
| Epigenetic biomarkers to track differentiation of pluripotent stem cells. | Stem Cell Reports | 2023 | 36460001 | PubTator, text mining | PubMed |
| Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer. | Cancer Med | 2023 | 36373163 | PubTator, text mining | PubMed |
| Malignant Perivascular Epithelioid Cell Tumor (PEComa) of the Uterus as Part of the Hereditary Cancer Syndrome: A Case Diagnosed with Multiple Malignancies. | Turk Patoloji Derg | 2023 | 36367123 | PubTator, text mining | PubMed |
The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study. | Cancer Med | 2023 | 36358026 | PubTator, text mining | PubMed |
| Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. | Clin Cancer Res | 2023 | 36318705 | PubTator, text mining | PubMed |
| Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants. | J Natl Cancer Inst | 2023 | 36315097 | PubTator, text mining | PubMed |
| Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea. | Ann Lab Med | 2023 | 36045058 | PubTator, text mining | PubMed |
| Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. | Clin Cancer Res | 2023 | 36043882 | PubTator, text mining | PubMed |
| A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. | J Clin Oncol | 2023 | 35960902 | PubTator, text mining | PubMed |
| 3'RNA and whole-genome sequencing of archival uterine leiomyomas reveal a tumor subtype with chromosomal rearrangements affecting either HMGA2, HMGA1, or PLAG1. | Genes Chromosomes Cancer | 2023 | 35822448 | PubTator, text mining | PubMed |
| Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). | J Clin Oncol | 2023 | 35737919 | PubTator, text mining | PubMed |
| Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation. | Cancer Res Treat | 2023 | 35681111 | PubTator, text mining | PubMed |
| Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer. | Cancer Res Treat | 2023 | 35410113 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5890/papers?page=16